statement
10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보이며, 약효 문제로 단정하기 어렵다.
A statement by 하나증권. Statements are as reported by the cited publishers — not verified by DecisionGateway.
10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보임(약효 문제라 단정하기 어려움)
Related claims
에피노페그듀타이드 10mg은 섬유화 개선 외 모든 항목에서 통계적 유의성을 충족했고, 보수적인 mITT 분석에서도 의미 있는 결과를 보였다.하나증권 · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statementIt is impossible to confirm the reliability of the figures.thebell_io · statementThis mechanism has proven its effectiveness in practice, and its active use is constantly expanding.Михаил Мишустин · statementThe confidence improvement follows three consecutive readings of deterioration.analisisbankinter · statement
More claims by 하나증권
The report reviewed trends and major economic indicators in the U.S. and Chinese stock markets and analyzed valuations and trends by global sector.statementThe U.S. should watch AI-related regulation and volatility in the semiconductor sector, while for China domestic demand stimulus and policy effects will be key to a sustained rebound.statementThis report is a weekly report covering global sector trends and indicators rather than a single earnings estimate for an individual company, and it does not provide annual aggregate earnings figures.statementAn approach centered on core theme ETFs such as generative AI, semiconductors, quality and cybersecurity, and on major big tech stocks, remains valid.statementAhead of Nvidia's earnings release on 11/18, market attention is focused on Blackwell demand and next-generation GPU supply outlook.statement
All claims by 하나증권